Multiple human papilloma virus types in cervical infections: Competition or synergy?

APMIS

Volumn 118, Issue 5, 2010, Pages 346-352

  Mejlhede, Nina ^a   Pedersen, Bo V ^a   Frisch, Morten ^a   Fomsgaard, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Coinfection; HPV types; Microarray; Multiple infection; Virus competition

Indexed keywords

ADOLESCENT; ALPHAPAPILLOMAVIRUS; ARTICLE; CONCURRENT INFECTION; CONTROLLED STUDY; CYTOLOGY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 51; INFECTION RISK; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MIXED INFECTION; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVICITIS; VACCINATION; VIRUS CELL INTERACTION; WART VIRUS;

EID: 77951117511     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2010.2602.x     Document Type: Article

References (22)

1. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007 195 : 1582 1589. (Pubitemid 46799215)
2. Mejlhede N, Bonde J, Fomsgaard A. High frequency of multiple HPV types in cervical specimens from Danish women. APMIS 2009 117 : 108 114.
3. Thomas KK, Hughes JP, Kuypers JM, Kiviat NB, Lee SK, Adam DE, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000 182 : 1097 1102.
4. Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001 183 : 8 15. (Pubitemid 32043036)
5. Rousseau MC, Abrahamowicz M, Villa LL, Costa MC, Rohan TE, Franco EL. Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2003 12 : 1029 1037. (Pubitemid 37310259)
6. Mendez F, Munoz N, Posso H, Molano M, Moreno V, van den Brule AJ, et al. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 2005 192 : 1158 1165.
7. Kjaer SK, Munk C, Winther JF, Jørgensen HO, Meijer CJ, van den Brule AJ. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 2005 14 : 1528 1533.
8. Lajous M, Mueller N, Cruz-Valdéz A, Aguilar LV, Franceschi S, Hernández-Avila M, et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 2005 14 : 1710 1716.
9. Harrell FE Jr. Regression Modelling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis.
10. Huang SL, Chao A, Hsueh S, Chao FY, Huang CC, Yang JE, et al. Comparison between the Hybrid Capture II Test and an SPF1/GP6+ PCR-based assay for detection of human papillomavirus DNA in cervical swab samples. J Clin Microbiol 2006 44 : 1733 1739.
11. Villa LL. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine 2006 24 (Suppl. 1 S23 8.
12. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med 2005 353 : 2101 2104.
13. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007 7 : 11 22.
14. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999 180 : 1415 1423.
15. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001 184 : 1508 1517.
16. Chaturvedi AK, Myers L, Hammons AF, Clark RA, Dunlap K, Kissinger PJ, et al. Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. Cancer Epidemiol Biomarkers Prev 2005 14 : 2439 2445. (Pubitemid 41437849)
17. Silins I, Wang Z, Avall-Lundqvist E, Frankendal B, Vikmanis U, Sapp M, et al. Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. J Gen Virol 1999 80 : 2931 2936.
18. Luostarinen T, Geijersstam V, Bjørge T, Eklund C, Hakama M, Hakulinen T, et al. No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer 1999 80 : 818 822.
19. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007 369 : 2161 2170.
20. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008 110 (Suppl. 1 S18 25.
21. Xi LF, Edelstein ZR, Meyers C, Ho J, Cherne SL, Schiffman M. Human papillomavirus types 16 and 18 DNA load in relation to coexistence of other types, particularly those in the same species. Cancer Epidemiol Biomarkers Prev 2009 18 : 2507 2512.
22. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995 87 : 1365 1371.